Incretin receptor masterclass today in the 🇨🇦 National Graduate Course in #islet biology and #diabetes from experts @daveyboyhod.bsky.social and @danieljdrucker.bsky.social from cell biology to translational impact #GLP1R #GIPR

Skip #cellculture with INDIGO Biosciences, INC all-inclusive, #luciferase reporter assay kits with an extensive selection of human and orthologs receptor assays for #drugdiscovery or for #environmental monitoring

🔗 tinyurl.com/yc69sreh

#GLP1R #CB1R #AndrogenReceptor #biotech

💊FDA Approval Update | 🙌 A big step in weight-loss science!
#FDA approval of the #Wegovy oral GLP-1 pill opens new possibilities for effective and non-injectable obesity treatments.
🌟MedChemExpress provides #Semaglutide for research use.
#Obesity #WeightLoss #GLP1 #GLP1R #WegovyOral

🧬Molecule of the Moment | #Pemvidutide (#ALT801)
A dual GLP-1R / GCGR agonist advancing across metabolic and liver disease indications.
Regulatory milestone: FDA Fast Track designation for #MASH and #AUD. We supports Pemvidutide for research use only. ow.ly/xk8F50XK5pg
#GLP1R

📰New & Featured | November New Releases
🚀1,000+ New Bioactive Molecules, targeting #WEE1 #HPK1 #MDM2 #TRPA1 #PARK7 #GLP1R
✔Reduce trial-and-error in early discovery
✔Access phase-advanced, high-selectivity research tools
#Oncology #Neuroscience #DrugDiscovery #ResearchTools

Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.
Bahar, Furkan et al.
Paper
Details
#GLP1R #CancerRisk #SystematicReview

Skip #cellculture with INDIGO Bio all-inc, #luciferase reporter assay kits with an extensive selection of human and orthologs receptor assays for #drugdiscovery or for #environmental monitoring 

🔗www.stratech.co.uk/our-partners/indigo-bios...

#GLP1R #CB1R #AndrogenReceptor #bioscience

#GLP1R #Pericyte

GLP1R agonist (Exendin-4) relaxes cardiac #Pericyte & dilates constricted capillaries in oxygen-glucose-derived perfused🐭right ventricle wall
A role of KATP channel Kir6.1

bioRxiv 2025
www.biorxiv.org/content/10.1...

LUXendin 492/551/555/615/645/651/762
Fluorescent Exendin4(9–39)

Visualize membrane #GLP1R in fixed/live cell & animals (retro-orbital or s.c. injection)
Also act as GLP1R antagonists

Are pancreatic Pericytes also labeled!?😍

#JACSAu 2022
pubs.acs.org/doi/10.1021/...

GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives Glucagon-like peptide-1 receptor agonists, originally developed for the treatment of metabolic disorders, have recently emerged as promising candidates for the management of substance use disorders. This review synthesizes preclinical, clinical, and translational evidence on the effects of glucagon-like peptide-1 receptor agonists across addiction models involving alcohol, nicotine, psychostimulants, and opioids. In animal studies, glucagon-like peptide-1 receptor agonists consistently reduce drug intake, attenuate dopamine release in reward circuits, and decrease relapse-like behavior. Clinical and observational studies provide preliminary support for these findings, particularly among individuals with comorbid obesity or insulin resistance. However, several translational barriers remain, including limited blood–brain barrier penetration, species differences in pharmacokinetics, and variability in treatment response due to genetic and metabolic factors. Ethical considerations and methodological heterogeneity further complicate clinical translation. Future directions include the development of central nervous system penetrant analogues, personalized medicine approaches incorporating pharmacogenomics, and rigorously designed trials in diverse populations. Glucagon-like peptide-1 receptor agonists may offer a novel therapeutic strategy that addresses both metabolic and neuropsychiatric dimensions of addiction, warranting further investigation to define their role in the evolving landscape of substance use disorder treatment.

🚨What if your #Diabetes meds could fight addiction too?🧠💥New review shows #GLP1R agonists slash #Alcohol, #Nicotine, stimulant, & opioid cravings in animal models🐀➡️Humans next? 🚀Time to rethink #Addiction treatment! @mdpiopenaccess.bsky.social #MentalHealth
doi.org/10.3390/ijms...

🚨What if your #Diabetes meds could fight addiction too?🧠💥New review shows #GLP1R agonists slash #Alcohol, #Nicotine, stimulant, & opioid cravings in animal models🐀➡️Humans next? 🚀Time to rethink #Addiction treatment! @mdpiopenaccess.bsky.social #Neuroscience #Pharma
doi.org/10.3390/ijms...

🚨What if your #Diabetes meds could fight addiction too?🧠💥New review shows #GLP1R agonists slash #Alcohol, #Nicotine, stimulant, & opioid cravings in animal models🐀➡️Humans next? 🚀Time to rethink #Addiction treatment! @mdpiopenaccess.bsky.social #MentalHealth #Innovation doi.org/10.3390/ijms...

🚨What if your #Diabetes meds could fight addiction too?🧠💥New review shows #GLP1R agonists slash #Alcohol, #Nicotine, stimulant, & opioid cravings in animal models🐀➡️Humans next? 🚀Time to rethink #Addiction treatment! @mdpiopenaccess.bsky.social #Pharmahttps://doi.org/10.3390/ijms26115338

🚨What if your #Diabetes meds could fight addiction too?🧠💥New review shows #GLP1R agonists slash #Alcohol, #Nicotine, stimulant, & opioid cravings in animal models🐀➡️Humans next? 🚀Time to rethink #Addiction treatment! @mdpiopenaccess.bsky.social #Neuroscience doi.org/10.3390/ijms...

🚨What if your #Diabetes meds could fight addiction too?🧠💥New review shows #GLP1R agonists slash #Alcohol, #Nicotine, stimulant, & opioid cravings in animal models🐀➡️Humans next? 🚀 Time to rethink #Addiction treatment! @mdpiopenaccess.bsky.social #Neuroscience #Pharma doi.org/10.3390/ijms...

GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice - Nature Metabolism This study, together with a companion manuscript, show that, in mice, weight loss as a result of GIP receptor antagonism requires, and potentiates, functional GLP-1 receptor signalling in the brain, e...

Using Sable Promethion #Metabolic Cages, a key study in Nature ties metabolic & genetic evidence to reveal how GIPR antagonists, but not agonists, need GLP-1R signaling to reduce #BodyWeight in mice. 🧪

ow.ly/8pPn50VNQGL

#Obesity #Diabetes #Metabolism #Neuroscience #GIP #GLP #GLP1R #DVC #snRNAseq

#GLP1R agonists show clinical promise in treating more than obesity and diabetes. In Sept 2024, we hosted a workshop exploring the potential for GLP-1 agonists to treat #CNSdisorders like substance use disorders, and more. Access the proceedings here: buff.ly/43fY2Tk

The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron Studies reveal pharmacological characteristics for activating the GLP-1 receptor with a nonpeptide agonist.

Discover the potential of orforglipron, a #GLP1R nonpeptide agonist, in tackling type 2 diabetes and obesity. This synthetic, oral therapy is shaping a scalable future! #medicine #innovation PMID:39693407, Sci Transl Med 2024 doi.org/10.1126/scit...

New brain targets for GLP1-based obesity drugs may reduce weight without nausea Researchers identified distinct hindbrain GLP1R neurons driving satiety and aversion, offering new targets for effective, side-effect-free obesity treatments.

New brain targets for GLP1-based obesity drugs may reduce weight without nausea 🔬📉🧠 www.news-medical.net/news/2024071... #Obesity #Research #GLP1R #WeightLoss #Neuroscience #Satiety #Nausea #Hindbrain #GLP1 #Medical @natureportfolio.bsky.social

Safety-focused summary of GLP-1 receptor agonists in diabetes, obesity, and beyond A recent review in Diabetes Care evaluates the efficacy and safety of GLP-1 receptor agonists for type 2 diabetes and obesity, exploring their potential for new medical indications.

Safety-focused summary of GLP-1 receptor agonists in diabetes, obesity, and beyond 🚀💉📊 www.news-medical.net/news/2024061... #Diabetes #GLP1R #Type2Diabetes #Obesity #MetabolicDisorders #WeightLoss

.@StructureTx IPO Raises $161M for Pills to Rival Blockbuster Biologics.
$GPCR #GPCR #GLP1R #diabetes #drugdiscovery #SBDD https://bit.ly/3Iao27T